RecruitingNCT06181812

Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

Prevalence of Pathogenic or Likely Pathogenic Germline Variants in Cancer Predisposition Genes Among Patients With Lung Adenocarcinoma


Sponsor

Oscar Gerardo Arrieta Rodríguez

Enrollment

332 participants

Start Date

Dec 15, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma. The main questions it aims to answer are: 1. What is the prevalence of pathogenic variants in genes associated with lung adenocarcinoma in Mexican patients younger than fifty? 2. Which clinical-pathological characteristics are associated with germ-line pathogenic variants in patients with lung adenocarcinoma? 3. How actionable somatic mutations are associated with germ line-pathogenic variants of patients with lung adenocarcinoma? Participants will be asked to sign an informed consent; after that, they will be instructed to donate 10 ml of peripheral blood by venipuncture in the morning and before the patient has taken morning medication and the first meal, following a period of 8-12 hr fasting.


Eligibility

Min Age: 16 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for inherited genetic mutations in people diagnosed with lung adenocarcinoma (a specific type of lung cancer) who may have a family history of the disease. Many people may not know they carry inherited gene changes that increase cancer risk. The study aims to identify these mutations to better understand and potentially screen families. **You may be eligible if...** - You are 16 years or older with a confirmed diagnosis of lung adenocarcinoma - You have a family history of lung cancer (a first-degree relative with lung cancer, or two or more second-degree relatives), OR - You are a never-smoker or light smoker with lung adenocarcinoma, OR - Your cancer has a specific mutation (e.g., EGFR, ALK, ROS1) even without a family history - You have signed informed consent **You may NOT be eligible if...** - You do not have a confirmed pathological diagnosis of lung adenocarcinoma - Your life expectancy is less than 8 weeks - You have declined genetic testing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología

Mexico City, Mexico City, Mexico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06181812


Related Trials